Witnessing the stock’s movement on the chart, on Thursday, Syros Pharmaceuticals Inc. (NASDAQ: SYRS) had a quiet start as it plunged -8.00% to $2.07, before settling in for the price of $2.25 at the close. Taking a more long-term approach, SYRS posted a 52-week range of $1.43-$8.17.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 128.79%. Meanwhile, its Annual Earning per share during the time was 21.16%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 64.31%. This publicly-traded company’s shares outstanding now amounts to $26.45 million, simultaneously with a float of $19.76 million. The organization now has a market capitalization sitting at $55.50 million. At the time of writing, stock’s 50-day Moving Average stood at $1.84, while the 200-day Moving Average is $4.88.
Syros Pharmaceuticals Inc. (SYRS) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Syros Pharmaceuticals Inc.’s current insider ownership accounts for 26.31%, in contrast to 56.07% institutional ownership. According to the most recent insider trade that took place on Sep 11 ’24, this organization’s President & CEO bought 50,000 shares at the rate of 1.71, making the entire transaction reach 85,420 in total value, affecting insider ownership by 122,504. Preceding that transaction, on Sep 12 ’24, Company’s Chief Financial Officer bought 45,344 for 1.68, making the whole transaction’s value amount to 76,006. This particular insider is now the holder of 124,552 in total.
Syros Pharmaceuticals Inc. (SYRS) Earnings and Revenue Records
Syros Pharmaceuticals Inc.’s EPS increase for this current 12-month fiscal period is 64.31% and is forecasted to reach -2.71 in the upcoming year.
Syros Pharmaceuticals Inc. (NASDAQ: SYRS) Trading Performance Indicators
Let’s observe the current performance indicators for Syros Pharmaceuticals Inc. (SYRS). It’s Quick Ratio in the last reported quarter now stands at 3.46. The Stock has managed to achieve an average true range (ATR) of 0.20. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 13.37.
In the same vein, SYRS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.30, a figure that is expected to reach -0.68 in the next quarter, and analysts are predicting that it will be -2.71 at the market close of one year from today.
Technical Analysis of Syros Pharmaceuticals Inc. (SYRS)
Going through the that latest performance of [Syros Pharmaceuticals Inc., SYRS]. Its last 5-days volume of 0.87 million indicated improvement to the volume of 0.23 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 50.87% While, its Average True Range was 0.22.
Raw Stochastic average of Syros Pharmaceuticals Inc. (SYRS) in the period of the previous 100 days is set at 11.64%, which indicates a major fall in contrast to 28.69% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 92.01% that was lower than 172.14% volatility it exhibited in the past 100-days period.
